about
T-cell clonotypes in cancerThe melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responsesNatural CD4+ T-cell responses against indoleamine 2,3-dioxygenaseAberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor ReactivityThe immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.Cytotoxic T cells.Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.The effect of short-chain fatty acids on human monocyte-derived dendritic cellsEstablishing the pig as a large animal model for vaccine development against human cancerRegulators of apoptosis: suitable targets for immune therapy of cancer.(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationAdoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.The universal character of the tumor-associated antigen survivin.The immunogenicity of the hTERT540-548 peptide in cancer.Cancer treatment: the combination of vaccination with other therapies.Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.Therapeutic cancer vaccines in combination with conventional therapy.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Immunotherapy for metastatic colorectal cancer: present status and new options.Cellular based cancer vaccines: type 1 polarization of dendritic cells.Immune-suppressive properties of the tumor microenvironment.Self-reactive T cells: suppressing the suppressors.The expression, function and targeting of haem oxygenase-1 in cancer.The targeting of immunosuppressive mechanisms in hematological malignancies.The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.Immunogenicity of Bcl-2 in patients with cancer.Oncogenic cancer/testis antigens: prime candidates for immunotherapy.Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.PD-L1-specific T cells.Anti-regulatory T cells.The role of dendritic cells in cancer.Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice.Cancer and autoimmunity.
P50
Q24803891-F67D6E71-9FCA-4F6A-A734-7FFA2A383ADCQ28249285-67BA7B2B-762B-4CB4-B56C-504E52E37FFFQ28730430-7A9D21AA-D66C-4B6A-9D31-5357D117BF79Q30040092-71F5E598-3898-4333-A60E-13522A8DBDD6Q33501195-3509E46F-1C8D-4283-9EA0-05585DBF3DADQ34485256-C7B4A9E5-0F3D-41CB-BAFC-CDB5A4C50623Q34508082-F30EC8FB-0CA1-48DB-9E81-BB4514E4C63BQ34707334-6642ACCD-C8FB-4F52-AB62-49C81AED1B98Q35682727-945A003C-DA51-45B2-A200-CA014ACE8738Q35692171-024BC450-D157-4C3C-A0D3-7B7A140BC9DDQ35833770-DAEADDB1-2556-4F01-BBC6-3C3371EC1B5EQ36097327-ECFF2827-5570-45AE-BA15-E1F4E4AD0714Q36111911-2C4F9402-5F3E-4EFB-A48E-3B6DC3492E1CQ36229571-FACE444C-66F7-45B8-92BB-C93A15FEC430Q36444798-868ED6A3-A986-485C-8C72-DDD699008D25Q36694942-93E1B12A-14A0-4541-94AA-D33F5C3475CCQ36813010-17DC609A-12DD-457A-8F19-938FB597F4F4Q36975578-788288CD-B8B3-423C-BED2-68789F78DBA3Q37048961-86F27577-91B7-4FF8-A3DE-16FE13686FD8Q37089001-E2BF0097-7762-4C50-814E-2A57961E581BQ37249394-3D3E0F06-E346-4B5C-A0C0-2245869570F5Q37574649-B7E8069D-7945-4B87-B9D8-B7A2541CBB95Q37771267-296FC9B8-A23F-4FC2-8309-CB5F194CD5B0Q37838167-9E8D24D3-CA84-457A-886A-2ED0612B65FAQ37972934-4FDF0A08-B070-48C7-8BD1-DAE7200038A1Q38029745-7E799D97-15CD-4743-A2A2-74CDAB1D0A98Q38105970-64394562-794C-4B8B-ACF6-924AB3FA675EQ38173811-C3250327-B946-4988-8ABF-BE94B755B6F9Q38198119-5CE11FC0-3265-4BA5-A44B-9A39CEF1FE12Q38201231-79778CA6-75C5-483D-8DDB-30A8628E2539Q38248051-016F264D-9649-4AD9-BC92-BF815E86D223Q38266251-7F74690E-1953-4F73-8BC9-F056232E90C9Q38336726-B185A912-68DC-447D-8EA2-7CBD9E2C288AQ38544350-7AC2E80F-A5CC-4A10-B82A-0049DFEB008BQ38550289-3DF4F12C-4B18-4092-B8CA-35A1294699B4Q38685359-71EAAAEB-8E46-4163-BC97-EB4E51FC168CQ38817090-9A8178F8-E256-4652-B336-EED712FF173CQ38957065-AF7E433C-DC4C-4836-960C-447FDAB1FDCAQ38993215-7A6CBF66-48E8-4869-B4F5-11B3E1B7DB27Q39204129-691D9ECF-EFB4-4766-AA1B-A73D60E2A332
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mads Hald Andersen
@ast
Mads Hald Andersen
@en
Mads Hald Andersen
@es
Mads Hald Andersen
@nl
type
label
Mads Hald Andersen
@ast
Mads Hald Andersen
@en
Mads Hald Andersen
@es
Mads Hald Andersen
@nl
prefLabel
Mads Hald Andersen
@ast
Mads Hald Andersen
@en
Mads Hald Andersen
@es
Mads Hald Andersen
@nl
P214
P106
P214
P31
P496
0000-0002-2914-9605
P7859
viaf-307237385